Up to two psilocybin doses for depression in people with cancer
About this title
Read the official source — NCT05947383Researchers are comparing Psilocybin and placebo to find out how the approaches affect depression symptoms in adults with depression.
Understand this study
What is this study about?
Researchers are comparing Psilocybin and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who could participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
- Listed locations
- RockvilleSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 56
- Sponsor
- Sunstone Medical
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT05947383
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer
Recruitment & locations
Rockville
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Psilocybin and placebo to find out how the approaches affect depression symptoms in adults with depression.
Who is behind this study?
The study sponsor is Sunstone Medical.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
